This first-of-its-kind process enables the company to produce cGMP-compliant, pure THC molecules to be used as the active pharmaceutical ingredient in products currently undergoing research for multiple conditions.
Dosing and labeling are currently big issues for cannabis consumers and these results could help improve the quality and consistency of cannabis extracts.
Though almost half of oncologists surveyed recommend medical marijuana clinically, less than a third feel equipped with enough knowledge to make such recommendations.
The trial is designed to assess the time-to-relief in patients suffering from severe pain.
Recent findings contrast with pre-existing data that shows the drug is linked to an increased chance of suicidal behaviour in the general population.
While cannabis flower characterized the market in the early years, cannabis extracts have become increasingly popular and eclipsed cannabis flower sales this year.